STAT+: la Corte Suprema della California si schiera con Gilead per il caso dell'innovazione

Eli Lilly has announced it will expand its special access program for retatrutide, an experimental obesity drug currently under review by the U.S. Food and Drug Administration. This follows reports that the company initially allowed a 79-year-old patient, described as being well-connected, to access the medication through the FDA's compassionate use program in April. Now, Lilly says it will consider applications from other patients seeking early access to the drug before it receives formal approval. The decision comes after several doctors raised concerns over the lack of transparency regarding the process for obtaining access to retatrutide. Some had reportedly submitted requests for early access but had not received responses from the company. According to internal communications obtained by STAT, Lilly has since committed to reviewing these requests and providing clearer guidance on how patients can apply for the drug. Meanwhile, in a separate development, the California Supreme Court ruled in favor of Gilead Sciences in a high-profile case involving allegations that the company delayed the development of a safer HIV treatment. The court's 6-1 decision overturned a previous ruling by a state appeals court, which had found Gilead potentially liable for failing to prioritize the development of a less harmful alternative to one of its existing drugs. The case, which drew national attention, stemmed from claims made by over 24,000 individuals who alleged they suffered kidney damage and bone loss due to long-term use of an older HIV medication. These plaintiffs argued that Gilead deliberately slowed the introduction of a newer, safer therapy to protect its market share. The California Supreme Court's ruling has sparked concern within the pharmaceutical industry, with some experts warning that the outcome might discourage companies from investing in new drug development due to fears of legal repercussions. The legal battle dates back to 2024 when the plaintiffs filed both federal and state lawsuits against Gilead. Their claims centered around the idea that the company had a duty to innovate and provide safer alternatives to its existing products. The appeals court had previously ruled that Gilead could be held responsible for not accelerating the development of the newer drug, citing ethical obligations tied to corporate responsibility in healthcare. Following the California Supreme Court's decision, Gilead issued a statement expressing relief and emphasizing its commitment to continuing research into innovative treatments for HIV. The company highlighted that its development timelines are based on rigorous scientific evaluation and regulatory requirements, rather than commercial considerations. The ruling has generated mixed reactions among stakeholders in the healthcare sector. While some advocates for patient rights expressed disappointment with the court's decision, others welcomed the clarification that pharmaceutical companies would not face undue legal pressure to expedite drug development processes. Industry analysts noted that the case underscores the complex balance between corporate accountability and the need for continued medical innovation. As the debate continues, regulatory bodies and lawmakers are likely to scrutinize the implications of the court's ruling. Discussions are expected to focus on whether current laws adequately address the responsibilities of pharmaceutical firms while still encouraging investment in new therapies. The outcome of this case may influence future legal strategies and policy discussions related to drug development and patient care.